title: Serum BMP-2 up-regulation as an indicator of poor survival in advanced non-small cell lung cancer patients.
abstract: OBJECTIVE
  High levels of bone morphogenetic protein (BMPs) have been reported in patients with lung cancer. This study was conducted to assess correlations between serum BMP-2 levels and prognostic outcome in patients with non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Blood samples from 84 patients with advanced NSCLC and 42 healthy controls were analyzed and quantitated for serum BMP-2 levels before and after two cycles of chemotherapy using a commercially available ELISA kit.
  
  
  RESULTS
  The median level of BMP-2 was 146.9 pg/ml in patients with NSCLC vs. 87.7 pg/ml in healthy controls (P<0.01). A significant correlation was observed between pretreatment serum BMP-2 level and ECOG PS, disease stage and number of organs with metastases (P<0.05). Serum BMP-2 level decreased significantly in patients who achieved objective response after two cycles of chemotherapy. Multivariate analysis showed that increased BMP-2 level and advanced clinical stage were significantly correlated with poor prognosis.
  
  
  CONCLUSIONS
  Thes erum BMP-2 level is positively correlated with clinical stage, ECOG PS and metastatic burden and may serve as an independent negative predictor for prognosis. Decreased BMP-2 after chemotherapy could be a reliable marker for efficacy of treatment.
authors.affiliation: The Second Clinical College, Zhejiang Chinese Medical University, Hangzhou, China E-mail : huangxinen06@aliyun.com, mashenglin@medmail.com.cn.
authors.forename: Zheng-Hua
authors.initials: ZH
authors.lastname: Fei
authors.forename: Cheng-Yun
authors.initials: CY
authors.lastname: Yao
authors.forename: Xiao-Lei
authors.initials: XL
authors.lastname: Yang
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Sheng-Lin
authors.initials: SL
authors.lastname: Ma
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000401:mortality* / Q000556:secondary; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D055396:Bone Morphogenetic Protein 2 / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000401:mortality* / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000401:mortality* / Q000556:secondary; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000401:mortality* / Q000473:pathology; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D015996:Survival Rate
chemical_list: C525718:BMP2 protein, human; D014408:Biomarkers, Tumor; D055396:Bone Morphogenetic Protein 2